Caisson Collaborates with CordenPharma to Develop Life Saving Therapeutics
FREMONT, CA: A biopharmaceutical company, Caisson Biotech, LLC (Caisson) recently announced their partnership with a full-service Contract Development and Manufacturing Organization (CDMO)—CordenPharma International (CordenPharma) that manufactures APIs and Drug Products through a network of Current Good Manufacturing Practice (cGMP) facilities across Europe and the U.S.
Caisson offers a patented drug delivery solution that provides both an economic advantage and improved safety for patients. Using the patented heparosan-based half-life extension and drug delivery platform—HEPtune—the Austin based firm demonstrated effective technology transfer and cGMP capacity with its corporate pharmaceutical partners. In order to provide licensing partners with HEPtune drug conjugate material, it is expected that Caisson will initiate homogeneous capabilities with CordenPharma.
HEPtune can be custom-built with respect to polymer size and conjugation chemistry by providing flexibility to intensify a variety of therapeutic proteins and peptides. Degraded through natural mechanisms, the polymer system is applicable to numerous drug types including proteins, peptides, aptamers, fragmented antibodies, small molecules, coordination complexes, as well as liposomal and micellar delivery systems. This heparosan-modified therapeutics will offer enhanced pharmacokinetics, drug performance properties, as well as advanced options for treatment and hope for patients, end users, particularly those who are undergoing long-term treatments.
To its credit, CordenPharma additionally holds expertise in synthetic lipid and carbohydrate manufacturing. As such, the firm being the developer of the HEPtune platform will leverage its experience and prowess in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates.
“We are excited to announce a manufacturing relationship with CordenPharma,” said Breca Tracy, PhD, Vice President and Managing Director of Caisson. “CordenPharma’s experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate Caisson’s capabilities to fulfill requests for larger quantities of quality material for pre-clinical and clinical studies.”
Mimoun Ayoub, PhD, Director, Global Peptides, Lipids, Carbohydrates and Injectables Platforms, CordenPharma International, said, “We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma’s Peptides, Lipids and Carbohydrates platform, and we look forward to supporting Caisson Biotech’s partners as they develop and commercialize novel, life-saving therapeutics.”
By Chris Tjotjos, VP, Cisco Solutions Practice, Black Box...
By Laura Jackson, Sr. Manager-Risk Management, ABS Consulting
By Jason Cradit, VP of Information Systems, Willbros Group
By Steve Garske, Ph.D., Senior Vice President & Chief...
By Roman Trakhtenberg, CEO, Luxoft
By Renee P Wynn, CIO, NASA
By Mike Morris, CIO, Legends
By Louis Carr, Jr., CIO, Clark County
By Andrew Macaulay, CTO, Topgolf Entertainment Group
By Dominic Casserley, President and Deputy CEO, Willis...
By Dave Nelson, SVP-Portfolio Lead, Avanade, Inc.
By Michael Cross, SVP & CIO, CommScope Holding Company Inc.
By Pauly Comtois, VP DevOps, Hearst Business Media
By Dan Adam, CIO, Extreme Networks
By Matt Schlabig, CIO, Worthington Industries
By David Tamayo, CIO, DCS Corporation
By Scott Cardenas, CIO, City and County of Denver
By Marc Kermisch, VP & CIO, Red Wing Shoe Co.
By Brian Drozdowicz, VP, Digital Services, Siemens...
By Les Ottolenghi, EVP and CIO, Caesars Entertainment